Data / Public companies / Texas / Pharmaceutical preparations
Pharmaceutical preparations companies in Texas: 21 that file annual reports with the SEC
21 companies that file annual reports with the SEC have a business address in Texas and the industry code SIC 2834 (Pharmaceutical preparations), in the SEC Financial Statement Data Sets filed through September 30, 2026. 6 report revenue, a combined $62.5 million. 0.0% of the 21 that report net income show a profit. The largest by revenue is Lexicon Pharmaceuticals, Inc. ($49.8 million).
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- 2834SIC code
- 21Companies with an annual report in the data
- 6Companies that report revenue
- $62.5 millionCombined revenue
- $2.3 millionMedian revenue
- 0 of 21 (0.0%)Reported a net profit
- $1.15 billionCombined total assets
- June 1, 2026Newest annual report filed
Largest by revenue
Latest fiscal year, from each company's annual report. Each name links to the company's page.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. | The Woodlands, TX | $49.8 million | $-50,341,000 | $185 million | 60.2% |
| Coya Therapeutics, Inc. | Houston, TX | $7.9 million | $-21,226,107 | $50 million | 123.6% |
| Marker Therapeutics, Inc. | Houston, TX | $3.5 million | $-12,163,620 | $19.1 million | -46.2% |
| Shattuck Labs, Inc. | Austin, TX | $1 million | $-48,809,000 | $91 million | -82.5% |
| Ainos, Inc. | Houston, TX | $124,157 | $-14,771,012 | $20.9 million | 499% |
| Impact Biomedical Inc. | Houston, TX | $32,000 | $-11,838,000 | $17.4 million | Not listed |
Companies by size of revenue
Companies that report revenue, by the revenue in their latest annual report.
| Revenue | Companies | Share |
|---|---|---|
| Under $10 million | 5 | 83.3% |
| $10 million to $100 million | 1 | 16.7% |
Cities with the most companies
By city of the business address.
| City | Companies | Share |
|---|---|---|
| Houston | 8 | 38.1% |
| Austin | 6 | 28.6% |
| Dallas | 2 | 9.5% |
| Fort Worth | 1 | 4.8% |
| Lakeway | 1 | 4.8% |
| Stafford | 1 | 4.8% |
| Sugar Land | 1 | 4.8% |
| The Woodlands | 1 | 4.8% |
Newest annual reports
By the date the company filed its latest annual report with the SEC.
| Company | Filed | Fiscal year ended | Form | Revenue |
|---|---|---|---|---|
| Greenwich Lifesciences, Inc. | June 1, 2026 | December 31, 2025 | 10-K | Not listed |
| CNS Pharmaceuticals, Inc. | March 31, 2026 | December 31, 2025 | 10-K | Not listed |
| Decoy Therapeutics Inc. | March 31, 2026 | December 31, 2025 | 10-K | Not listed |
| Forte Biosciences, Inc. | March 31, 2026 | December 31, 2025 | 10-K | Not listed |
| Tvardi Therapeutics, Inc. | March 31, 2026 | December 31, 2025 | 10-K | Not listed |
| Lantern Pharma Inc. | March 30, 2026 | December 31, 2025 | 10-K | Not listed |
| Genprex, Inc. | March 30, 2026 | December 31, 2025 | 10-K | Not listed |
| Ainos, Inc. | March 30, 2026 | December 31, 2025 | 10-K | $124,157 |
| Actuate Therapeutics, Inc. | March 26, 2026 | December 31, 2025 | 10-K | Not listed |
| Rein Therapeutics, Inc. | March 26, 2026 | December 31, 2025 | 10-K | $0 |
| Moleculin Biotech, Inc. | March 18, 2026 | December 31, 2025 | 10-K | $0 |
| Marker Therapeutics, Inc. | March 18, 2026 | December 31, 2025 | 10-K | $3.5 million |
Updated September 30, 2026. Read from SEC Financial Statement Data Sets (sec.gov). Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.